Impact Biomedical (IBO) FCF Margin (2025 - 2026)
Impact Biomedical's (IBO) quarterly FCF Margin came in at 15666.67% in Q2 2026, up 2558095.0% on a YoY basis from N/an in Q2 2025, and up 336.35% quarter-over-quarter from 6628.57% in Q1 2026.
Powered by 
Analysis
Impact Biomedical (IBO) FCF Margin (2025 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported FCF Margin for 2 consecutive years, with 15666.67% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 2558095.0% year-over-year to 15666.67%; the trailing twelve-month figure through Jun 2026 stood at 1451.43% (up 444857.0% YoY), and the FY2022 full-year result was 5036.0%, changed N/A from the prior year.
- FCF Margin rose to 15666.67% in Q2 2026 per IBO's latest filing, from 6628.57% in the prior quarter.
- Across five years, FCF Margin topped out at 15666.67% in Q2 2026 and bottomed at 9914.29% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | 15,666.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15,666.67% |
| Mar 31, 2026 | -6,628.57% |
| Sep 30, 2025 | -3,405.56% |
| Jun 30, 2025 | -9,914.29% |